Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

  • 1 of 1

NHS England has set out plans to accelerate and widen the NHS’s use of biosimilars to cut up to £300m a year from the drug bill by 2021

Warwick Smith, director general of the British Biosimilars Association, said biosimilars are already helping the NHS treat more patients

Source  Courtesy of British Generic Manufacturers Association (BGMA)